Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations
Identifieur interne : 003B73 ( Main/Exploration ); précédent : 003B72; suivant : 003B74Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations
Auteurs : Connie Marras [Canada] ; Anthony Lang [Canada] ; Murray Krahn [Canada] ; George Tomlinson [Canada] ; Gary Naglie [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-01.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Benzothiazoles, Carbidopa (adverse effects), Carbidopa (therapeutic use), Double-Blind Method, Drug Combinations, Dyskinesia, Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (psychology), Female, Fluctuations, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Neurologic Examination (drug effects), Pain Measurement, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Quality of Life (psychology), Quality of life, Thiazoles (adverse effects), Thiazoles (therapeutic use), dopamine agonists, dyskinesia, levodopa, motor fluctuations, quality of life.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Carbidopa, Levodopa, Thiazoles.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Levodopa, Thiazoles.
- diagnosis : Dyskinesia, Drug-Induced, Parkinson Disease.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- psychology : Dyskinesia, Drug-Induced, Parkinson Disease, Quality of Life.
- Aged, Benzothiazoles, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Pain Measurement.
Abstract
The impact of dyskinesias and motor fluctuations on quality of life (QOL) at various stages in the course of Parkinson's disease (PD) is not well understood. In 301 subjects with early PD enrolled in a clinical trial (CALM‐PD), we quantified the impact of motor complications on QOL and investigated how this changes over time. We also compared QOL related to demographic and treatment characteristics. The presence of dyskinesias was associated with visual analogue scale (VAS) scores 3.0 of 100 points higher (better) than those without dyskinesias in years 1 to 2, even when adjusting for Unified Parkinson's Disease Rating Scale (UPDRS) motor scores. The positive association between dyskinesias and QOL scores was more marked in older patients. In years 3 to 4, dyskinesias no longer had a significant relationship with QOL. Younger subjects had higher VAS scores. Gender, motor fluctuations, and treatment regimen had no significant association with QOL, although a trend was found toward a small negative effect of motor fluctuations on QOL. We conclude that motor complications that occur within the first 4 years of treatment of PD do not have a significant negative effect on quality of life as measured by a visual analogue scale for most patients. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10642
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001096
- to stream Istex, to step Curation: 001096
- to stream Istex, to step Checkpoint: 002554
- to stream PubMed, to step Corpus: 003581
- to stream PubMed, to step Curation: 003581
- to stream PubMed, to step Checkpoint: 003343
- to stream Ncbi, to step Merge: 000C83
- to stream Ncbi, to step Curation: 000C83
- to stream Ncbi, to step Checkpoint: 000C83
- to stream Main, to step Merge: 005531
- to stream PascalFrancis, to step Corpus: 002232
- to stream PascalFrancis, to step Curation: 000A89
- to stream PascalFrancis, to step Checkpoint: 002032
- to stream Main, to step Merge: 005870
- to stream Main, to step Curation: 003B73
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name></author><author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name></author><author><name sortKey="Krahn, Murray" sort="Krahn, Murray" uniqKey="Krahn M" first="Murray" last="Krahn">Murray Krahn</name></author><author><name sortKey="Tomlinson, George" sort="Tomlinson, George" uniqKey="Tomlinson G" first="George" last="Tomlinson">George Tomlinson</name></author><author><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D161986F3E485F50A687006C42941C68586625F9</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.10642</idno><idno type="url">https://api.istex.fr/document/D161986F3E485F50A687006C42941C68586625F9/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001096</idno><idno type="wicri:Area/Istex/Curation">001096</idno><idno type="wicri:Area/Istex/Checkpoint">002554</idno><idno type="wicri:doubleKey">0885-3185:2004:Marras C:quality:of:life</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:14743356</idno><idno type="wicri:Area/PubMed/Corpus">003581</idno><idno type="wicri:Area/PubMed/Curation">003581</idno><idno type="wicri:Area/PubMed/Checkpoint">003343</idno><idno type="wicri:Area/Ncbi/Merge">000C83</idno><idno type="wicri:Area/Ncbi/Curation">000C83</idno><idno type="wicri:Area/Ncbi/Checkpoint">000C83</idno><idno type="wicri:doubleKey">0885-3185:2004:Marras C:quality:of:life</idno><idno type="wicri:Area/Main/Merge">005531</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0232991</idno><idno type="wicri:Area/PascalFrancis/Corpus">002232</idno><idno type="wicri:Area/PascalFrancis/Curation">000A89</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002032</idno><idno type="wicri:doubleKey">0885-3185:2004:Marras C:quality:of:life</idno><idno type="wicri:Area/Main/Merge">005870</idno><idno type="wicri:Area/Main/Curation">003B73</idno><idno type="wicri:Area/Main/Exploration">003B73</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Krahn, Murray" sort="Krahn, Murray" uniqKey="Krahn M" first="Murray" last="Krahn">Murray Krahn</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Clinical Decision Making and Health Care Research, Toronto General Research Institute, Toronto General Hospital, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of General Internal Medicine, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Medicine and Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Tomlinson, George" sort="Tomlinson, George" uniqKey="Tomlinson G" first="George" last="Tomlinson">George Tomlinson</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Radiology, University Health Network and Department of Biostatistics, University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Clinical Decision Making and Health Care Research, Toronto General Research Institute, Toronto General Hospital, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of General Internal Medicine, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Geriatrics Program, Toronto Rehabilitation Institute, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Medicine and Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-01">2004-01</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="22">22</biblScope><biblScope unit="page" to="28">28</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D161986F3E485F50A687006C42941C68586625F9</idno><idno type="DOI">10.1002/mds.10642</idno><idno type="ArticleID">MDS10642</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Benzothiazoles</term><term>Carbidopa (adverse effects)</term><term>Carbidopa (therapeutic use)</term><term>Double-Blind Method</term><term>Drug Combinations</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (diagnosis)</term><term>Dyskinesia, Drug-Induced (psychology)</term><term>Female</term><term>Fluctuations</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Neurologic Examination (drug effects)</term><term>Pain Measurement</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Quality of Life (psychology)</term><term>Quality of life</term><term>Thiazoles (adverse effects)</term><term>Thiazoles (therapeutic use)</term><term>dopamine agonists</term><term>dyskinesia</term><term>levodopa</term><term>motor fluctuations</term><term>quality of life</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term><term>Thiazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term><term>Thiazoles</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term><term>Quality of Life</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Benzothiazoles</term><term>Double-Blind Method</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pain Measurement</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term><term>Fluctuation</term><term>Parkinson maladie</term><term>Qualité vie</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The impact of dyskinesias and motor fluctuations on quality of life (QOL) at various stages in the course of Parkinson's disease (PD) is not well understood. In 301 subjects with early PD enrolled in a clinical trial (CALM‐PD), we quantified the impact of motor complications on QOL and investigated how this changes over time. We also compared QOL related to demographic and treatment characteristics. The presence of dyskinesias was associated with visual analogue scale (VAS) scores 3.0 of 100 points higher (better) than those without dyskinesias in years 1 to 2, even when adjusting for Unified Parkinson's Disease Rating Scale (UPDRS) motor scores. The positive association between dyskinesias and QOL scores was more marked in older patients. In years 3 to 4, dyskinesias no longer had a significant relationship with QOL. Younger subjects had higher VAS scores. Gender, motor fluctuations, and treatment regimen had no significant association with QOL, although a trend was found toward a small negative effect of motor fluctuations on QOL. We conclude that motor complications that occur within the first 4 years of treatment of PD do not have a significant negative effect on quality of life as measured by a visual analogue scale for most patients. © 2003 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name></noRegion><name sortKey="Krahn, Murray" sort="Krahn, Murray" uniqKey="Krahn M" first="Murray" last="Krahn">Murray Krahn</name><name sortKey="Krahn, Murray" sort="Krahn, Murray" uniqKey="Krahn M" first="Murray" last="Krahn">Murray Krahn</name><name sortKey="Krahn, Murray" sort="Krahn, Murray" uniqKey="Krahn M" first="Murray" last="Krahn">Murray Krahn</name><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name><name sortKey="Tomlinson, George" sort="Tomlinson, George" uniqKey="Tomlinson G" first="George" last="Tomlinson">George Tomlinson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D161986F3E485F50A687006C42941C68586625F9
|texte= Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations
}}
| This area was generated with Dilib version V0.6.23. |  |